<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323659</url>
  </required_header>
  <id_info>
    <org_study_id>PLRG-14</org_study_id>
    <nct_id>NCT02323659</nct_id>
  </id_info>
  <brief_title>Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas</brief_title>
  <official_title>Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Lymphoma Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polish Lymphoma Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life
      in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methotrexate and interferon are widely used drugs in treatment in patients with cutaneous
      T-cell Lymphomas. Efficacy and safety of both drugs have never been compared directly in one
      study.

      Patients will be randomly assigned to receive Methotrexate or Interferon Alfa 2b. Treatment
      will continue until disease progression or the development of intolerable toxicities. Study
      is conducted to analyse and compare efficacy, safety and quality of life provided by
      Methotrexate or Interferon Alfa 2b.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate as measured by the modified Severity Weighted Assessment Tool (mSWAT scoring system)</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluation according to modified Severity Weighted Assessment Tool (mSWAT scoring system)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by the Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluation according to Dermatology Life Quality Index (DLQI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lymphoma, T-Cell, Cutaneous</condition>
  <condition>Mycosis Fungoides</condition>
  <arm_group>
    <arm_group_label>Methotrexate arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to receive methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon Alfa-2b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to receive Interferon alfa 2b</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate 20mg per dose, administered orally, once every week</description>
    <arm_group_label>Methotrexate arm</arm_group_label>
    <other_name>Tranxene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Alfa-2b</intervention_name>
    <description>Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week</description>
    <arm_group_label>Interferon Alfa-2b</arm_group_label>
    <other_name>Intron A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed primary cutaneous T-cell lymphoma (CTCL)

          2. Age ≥ 18 years

          3. Performance status WHO&lt;=2

          4. Subject must have adequate bone marrow, renal and hepatic function

          5. Topical and phototherapy treatment failure in the past

          6. Signed informed consent

        Exclusion Criteria:

          1. Subject has received prior systemic methotrexate or interferon therapy

          2. Unacceptable methotrexate or interferon treatment toxicity in the past

          3. Inadequate bone marrow, renal or hepatic function as follows:

               -  Bone Marrow: Absolute neutrophil count (ANC) &lt; 1,500/mm 3 (1.5 × 10 9 /L);
                  Platelets &lt;100,000/mm 3 (100 × 10 9 /L); Hemoglobin &lt; 9.0 g/dL (1.4 mmol/L);

               -  Renal function: Creatinine &gt;1.5 x Upper limit of normal (ULN)

               -  Hepatic function: Aspartate and Alanine transaminase (AST and ALT) &gt;3× ULN;
                  bilirubin &gt; 1.5 × ULN

               -  Active hepatitis B or hepatitis C

          4. anorexia

          5. major depression with suicidal ideation or suicide attempt in the past

          6. Symptomatic congestive heart failure

          7. Epilepsia or other symptomatic central nervous system dysfunction

          8. active skin infection not related to underlying CTCL, active Tuberculosis, HIV
             infection

          9. Subject is pregnant or lactating

         10. Psychiatric illness/social situation that would limit compliance with study
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Małgorzata Sokołowska Wojdyło, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polish Lymphoma Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ewa Chmielowska, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polish Lymphoma Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ewa Chmielowska, MD, PhD</last_name>
    <phone>48523743421</phone>
    <email>eacagace@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centrum Onkologii im. prof. F. Łukaszczyka</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Chmielowska, MD, PhD</last_name>
      <phone>48523743421</phone>
      <email>eacagaca@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycosis Fungoides</keyword>
  <keyword>Cutaneous T-Cell Lymphoma</keyword>
  <keyword>Interferon</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

